Latest news
Loading news…
Akroswiss
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Zug, Switzerland Founded 2007 1-10 employees For Profit
Akroswiss develops and commercializes intranasal midazolam therapies and bi-dose delivery devices for seizure treatment and sedation.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
1
Patents
2
5 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 3
- Patents granted
- 2
- Trademarks
- 5
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $105K
Company Info
- Founded
- 2007
- Employees
- 1-10
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 3
- HQ
- Zug, Switzerland
- Region
- Europe, Middle East, and Africa (EMEA)
Signals & Scores
- Heat score
- Medium
- Growth score
- Low
- Trend (7d)
- 0.1
- Trend (30d)
- -0.2
- Trend (90d)
- -0.5
Key People at Akroswiss
Founder & Chief Scientific Officer
Chief Executive Officer
1
professional contacts at Akroswiss
Contact execs at Akroswiss →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Akroswiss
Loading news…
FAQs about Akroswiss
People who checked this page also checked these
Browse the full Acquirezy directory.